Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipovirtide Combined With Nucleoside Drugs in Treatment-Naive HIV-infected Patients
NCT06061536Phase 2Completed
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lipovirtide in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Shanxi Kangbao Biological Products. Primary endpoint: Proportion of Participants with HIV-1 RNA <50 copies/ml at Day 169. Started Nov 2023; status: completed.
02
Drugs
lipovirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06061536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061536.